Health · Pharma & Biotech · 2 days ago
US FDA approves Asahi Kasei drug for persistent herpes infections
The US FDA has approved an Asahi Kasei drug for persistent herpes infections.
The approval concerns infections described as persistent.
The drug's name is not provided.
The available information does not explain how it works or who may receive it.
It gives no details about trial results, side effects or access.
No next steps are specified.
The US Food and Drug Administration approved a drug developed by Asahi Kasei.
The drug is for persistent herpes infections.
The article was published on October 9, 2026.
- Who
- The US Food and Drug Administration and Asahi Kasei
- What
- The FDA approved an Asahi Kasei drug for persistent herpes infections.
- When
- October 9, 2026
- Where
- United States
- Why
- To treat persistent herpes infections
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Regulator
- US Food and Drug Administration
- Company
- Asahi Kasei
- Indication
- Persistent herpes infections
- Publication date
- October 9, 2026
Sources
Related news
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
Brazil suspends Peptistrong supplement and orders all batches recalled
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
Daily painkiller use can hide the cause of ongoing pain
Swiss oncologist warns US drug pricing pressure could delay cancer therapies
